A Phase II/III Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine
the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis